Compare AdaptHealth Corp (AHCO) vs Manhattan Associates Inc (MANH) Price & Performance

AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.

Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.

MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.

The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.